Joseph Lyssikatos Sells 20,000 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph Lyssikatos sold 20,000 shares of the stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $26.75, for a total value of $535,000.00. Following the completion of the transaction, the insider directly owned 745,188 shares in the company, valued at $19,933,779. This represents a 2.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Enliven Therapeutics Stock Down 4.6%

Enliven Therapeutics stock opened at $25.78 on Friday. The stock has a 50-day moving average price of $20.43 and a 200 day moving average price of $20.36. The company has a market capitalization of $1.53 billion, a price-to-earnings ratio of -14.01 and a beta of 0.41. Enliven Therapeutics, Inc. has a 52 week low of $13.30 and a 52 week high of $29.98.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.11. Research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Analysts Set New Price Targets

ELVN has been the topic of several recent research reports. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.00.

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. grew its holdings in Enliven Therapeutics by 30.2% in the third quarter. JPMorgan Chase & Co. now owns 24,818 shares of the company’s stock valued at $508,000 after purchasing an additional 5,754 shares during the period. Tudor Investment Corp ET AL purchased a new position in shares of Enliven Therapeutics during the 3rd quarter valued at approximately $334,000. Vestal Point Capital LP grew its stake in Enliven Therapeutics by 364.0% in the 3rd quarter. Vestal Point Capital LP now owns 1,160,000 shares of the company’s stock valued at $23,745,000 after acquiring an additional 910,000 shares during the period. Polar Capital Holdings Plc increased its holdings in Enliven Therapeutics by 1.5% in the 3rd quarter. Polar Capital Holdings Plc now owns 3,095,007 shares of the company’s stock worth $63,355,000 after acquiring an additional 44,713 shares in the last quarter. Finally, Millennium Management LLC raised its position in Enliven Therapeutics by 19.8% during the third quarter. Millennium Management LLC now owns 381,405 shares of the company’s stock worth $7,807,000 after acquiring an additional 62,956 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.